Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s00280-012-1943-6
Title: | A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy | Authors: | Kim, Y.H Muro, K Yasui, H Chen, J.-S Ryu, M.-H Park, S.-H Chu, K.-M Choo, S.-P Sanchez, T DelaCruz, C Mukhopadhyay, P Lainas, I Li, C.-P |
Keywords: | fluoropyrimidine derivative ixabepilone adjuvant therapy adult advanced cancer alopecia arthralgia article Asian asthenia bleeding Chinese constipation continuous infusion decreased appetite diarrhea drug dose reduction drug efficacy drug eruption drug fatality drug treatment failure drug withdrawal dysgeusia fatigue febrile neutropenia female fever human hypesthesia Japanese Korean leukopenia major clinical study male multicenter study multiple cycle treatment myalgia nail disease nausea neutropenia open study peripheral neuropathy phase 2 clinical trial pneumonia priority journal progression free survival pruritus sensory neuropathy sepsis side effect stomach cancer stomatitis thrombocytopenia treatment outcome vomiting weight reduction Adult Aged Antineoplastic Combined Chemotherapy Protocols Epothilones Female Fluorouracil Humans Male Middle Aged Stomach Neoplasms Tubulin Modulators |
Issue Date: | 2012 | Citation: | Kim, Y.H, Muro, K, Yasui, H, Chen, J.-S, Ryu, M.-H, Park, S.-H, Chu, K.-M, Choo, S.-P, Sanchez, T, DelaCruz, C, Mukhopadhyay, P, Lainas, I, Li, C.-P (2012). A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemotherapy and Pharmacology 70 (4) : 583-590. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-012-1943-6 | Rights: | Attribution 4.0 International | Abstract: | Purpose The highest rates of gastric cancer occur in Eastern Asia. Fluoropyrimidine-based therapy is used initially in unresectable and metastatic disease, but no single standard of care exists following disease progression. Ixabepilone, an epothilone B analog, is a non-taxane microtubule- stabilizing agent with clinical activity across multiple tumor types approved by the United States Food and Drug Administration for treatment of metastatic breast cancer. Methods Asian patients with unresectable or metastatic gastric adenocarcinoma who had failed fluoropyrimidinebased chemotherapy received ixabepilone 40 mg/m2 by 3-h intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR). Results Fifty-two patients were treated (65.4 % men; median age: 56.5 years). The ORR was 15.4 % (95 % confidence interval [CI] 6.9-28.1); 8 patients achieved partial responses for a median duration of 3.1 months (95 % CI 2.6-4.1 months) and 26 patients (50.0 %) had stable disease. Median progression-free survival was 2.8 months (95 % CI 2.1-3.5 months). The most common grade 3 non-hematological toxicities were fatigue (9.6 %), decreased appetite (7.7 %), sensory neuropathy (5.8 %), and diarrhea (5.8 %). Grade 3/4 neutropenia occurred in 46.2 % of patients. Conclusions Ixabepilone is active in Asian patients with advanced gastric cancer and shows a toxicity profile similar to those previously reported in other tumor types. © Springer-Verlag 2012. | Source Title: | Cancer Chemotherapy and Pharmacology | URI: | https://scholarbank.nus.edu.sg/handle/10635/180819 | ISSN: | 0344-5704 | DOI: | 10.1007/s00280-012-1943-6 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1007_s00280-012-1943-6.pdf | 211.17 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License